DOR BioPharma, Inc. Provides Financial Guidance And Update On European Regulatory Plans For orBec(R)

MIAMI--(BUSINESS WIRE)--Feb. 8, 2006--DOR BioPharma, Inc. (AMEX:DOR) ("DOR", or the "Company") announced today that it is focusing its resources on the preparation of New Drug Application ("NDA") and Marketing Authorization Application ("MAA") submissions and potential regulatory approvals for orBec(R) for the treatment of intestinal Graft-versus-Host disease ("iGVHD"). The Company is also providing guidance regarding its projected rate of cash expenditures for 2006. The Company believes it can achieve its current strategic goals for the year with average quarterly cash expenditures of approximately $800,000, or about $270,000 per month, although first quarter expenditures will likely be a little higher.